NCT01263418 2015-10-12
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline
GlaxoSmithKline
Nevada Cancer Institute